DEFA14A: Hologic Updates Merger Proxy Amid Lawsuits, Product Recall

Hologic, Inc. filed a definitive additional proxy statement to address stockholder lawsuits regarding its merger disclosures and announced a voluntary recall of its Brevera Breast Biopsy System needles.

Summary

• Hologic, Inc. (Hologic) entered into a Merger Agreement on October 21, 2025, with Hopper Parent Inc. and Hopper Merger Sub Inc., where Hologic will become a wholly owned subsidiary of Parent.
• Several class action and individual lawsuits, along with demand letters, have been filed by purported stockholders alleging omissions of material information in the Definitive Proxy Statement regarding the Merger.
• The lawsuits seek to enjoin the stockholder vote on the Merger unless the purportedly material information is disclosed.
• Hologic believes the allegations are without merit but is supplementing the Definitive Proxy Statement to avoid delays and minimize litigation costs.
• The company initiated a voluntary recall of its Brevera Breast Biopsy System Disposable 9 Gauge Needles in consultation with the FDA, following a stop-ship initiated in November 2025.
• The stop-ship of Brevera 9 Gauge Needles may be prolonged, impacting Breast Health revenue, which constituted approximately 4.7% of Breast Health revenue for fiscal year 2025.
• The Brevera stop-ship makes it more challenging to achieve the 2026 milestone under the contingent value right (CVR) agreement.
• The risk-adjusted net present value of one CVR is now believed to be less than the $2.54 per CVR previously stated in the Definitive Proxy Statement.
• Hologic reached an agreement in principle in November 2025, formalized on January 7, 2026, to settle BioZorb product liability litigation involving approximately 200 plaintiffs.
• The BioZorb settlement amount is fully covered by insurance, and Hologic expects to bear no financial liability.

Sentiment

Score: 3

Explanation: The filing contains significant negative news regarding a product recall with prolonged impact on revenue and CVR value, coupled with ongoing litigation challenging the merger proxy. While a BioZorb settlement is positive, it is overshadowed by these other issues. The overall sentiment is negative due to operational challenges and legal uncertainties impacting a key strategic event (the merger).

Positives

• The BioZorb product liability litigation, involving approximately 200 plaintiffs, has been settled with no admission of liability.
• The BioZorb settlement amount is fully covered by insurance, and Hologic expects to bear no financial liability related to the agreement.

Negatives

• Purported stockholders have filed class action and individual lawsuits, along with demand letters, alleging disclosure deficiencies in the Definitive Proxy Statement related to the Merger.
• The lawsuits seek to enjoin the stockholder vote on the Merger, potentially causing delays.
• Hologic initiated a voluntary recall of its Brevera Breast Biopsy System Disposable 9 Gauge Needles, following a stop-ship in November 2025.
• The stop-ship of Brevera 9 Gauge Needles is expected to be prolonged, impacting Breast Health revenue.
• Revenue from Brevera 9 Gauge Needles and related products represented approximately 4.7% of Breast Health revenue for fiscal year 2025.
• The Brevera stop-ship makes it more challenging to achieve the 2026 milestone under the contingent value right (CVR) agreement.
• The risk-adjusted net present value of one CVR is now believed to be less than the $2.54 per CVR previously stated in the Definitive Proxy Statement.

Risks

• The outcome of the stockholder lawsuits and demand letters cannot be predicted, and they could delay or adversely affect the Merger.
• Additional complaints and/or demand letters arising out of the Merger may be filed or received in the future.
• There is uncertainty regarding the duration of the Brevera 9 Gauge Needles stop-ship and the potential impact of mitigation measures on Breast Health revenue.
• There is no assurance that Breast Health revenue will equal or exceed the catch-up milestone during the 2027 milestone period, which could affect CVR payments.
• The timing, receipt, and terms of governmental and regulatory approvals for the proposed transaction could delay or cause abandonment of the Merger.
• The Merger Agreement could be terminated due to various events, changes, or circumstances.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the Merger Agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The proposed transaction could disrupt management time from ongoing business operations.
• Announcements relating to the proposed transaction could have adverse effects on the market price of Hologic's common stock.
• Unexpected costs or expenses may result from the proposed transaction.
• Litigation relating to the proposed transaction poses a risk.
• The proposed transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships, impacting operating results and business generally.
• Holders of the CVRs may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

Hologic expects the stop-ship of its Brevera Breast Biopsy System 9 Gauge Needles to be prolonged, which will make it more challenging to achieve the 2026 milestone under the contingent value right (CVR) agreement. Consequently, the risk-adjusted net present value of one CVR is now believed to be less than the $2.54 per CVR previously stated. The company also anticipates the merger with Hopper Parent Inc. to proceed, subject to various conditions and the resolution of ongoing litigation.

Management Comments

• "The Company believes that the allegations contained in these Matters are without merit."
• "The Company continues to expect that the stop ship of Brevera 9 Gauge Needles may be prolonged."
• "The Company continues to believe that it will be more challenging to achieve the 2026 milestone under the contingent value right (CVR) agreement."
• "The Company is unable to estimate with reasonable precision the risk adjusted net present value of one CVR at this time but the Company believes that the risk adjusted net present value of one CVR as of the date hereof is likely less than the $2.54 per CVR set forth in the Definitive Proxy Statement."

Industry Context

This filing primarily addresses company-specific events related to an ongoing merger, associated litigation, and a product recall. While Hologic operates in the medical device and diagnostics industry, the disclosures do not provide broad insights into industry trends or competitive landscape beyond the company's specific operational and strategic challenges.

Comparison to Industry Standards

• Goldman Sachs' discounted cash flow analysis utilized perpetuity growth rates estimated by taking into account market expectations regarding long-term real growth of gross domestic product and inflation.
• Illustrative NTM P/E multiples were derived based on professional judgment and experience, considering current and historical NTM P/E multiples for Hologic.
• Acquisition premia analysis reviewed 67 transactions announced from January 1, 2020, through October 17, 2025, involving public U.S. target companies (excluding biopharmaceuticals) with disclosed enterprise values greater than $10 billion. This analysis indicated a median premium of 24.4%, a 25th percentile premium of 15.2%, and a 75th percentile premium of 34.9%.

Corporate Governance

Legal Proceedings

• Class action lawsuit: Southfield Fire & Police Retirement System v. Hologic, Inc. et al., Case No. 2026-0060-BWD (Del. Ch. January 14, 2026), alleging disclosure omissions in the Definitive Proxy Statement.
• Individual actions: Smith v. Hologic, Inc., et al., No. 650252/2026 (filed on January 14, 2026), and Thomas v. Hologic, Inc., et al., No. 650272/2026 (filed on January 15, 2026), alleging similar disclosure omissions.
• Demand letters received from purported stockholders since December 15, 2025, alleging disclosure deficiencies in the Preliminary and Definitive Proxy Statements.
• Settlement of BioZorb product liability litigation: An agreement in principle was reached in November 2025, formalized on January 7, 2026, to resolve complaints from approximately 200 plaintiffs, with no admission of liability and fully covered by insurance.

Stakeholder Impact

• Shareholders: Face uncertainty regarding the merger timeline due to litigation, potential for reduced CVR payments, and the impact of the Brevera recall on future company performance.
• Customers: Users of the Brevera Breast Biopsy System Disposable 9 Gauge Needles are affected by the voluntary recall and prolonged stop-ship.
• Employees: May experience disruption and uncertainty related to the ongoing merger process.

Next Steps

• Stockholders will vote on the proposed Merger.
• Hologic will continue to analyze the potential impact of the Brevera stop-ship on Breast Health revenue and implement mitigating measures.
• The company will monitor the duration of the Brevera stop-ship.
• Resolution of the ongoing litigation related to the Merger proxy statement.
• Potential for a CVR catch-up payment during the 2027 milestone period if specific revenue targets are met.

Key Dates

Keywords

Hologic, HOLX, Merger, Proxy Statement, Litigation, Product Recall, Brevera, Breast Biopsy, CVR, Contingent Value Right, BioZorb, Settlement, SEC Filing, Corporate Governance, Healthcare, Medical Devices